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ABSTRACT
Castration resistant prostate cancer (CRPC) is a stage of relapse that arises after 
various forms of androgen ablation therapy (ADT) and causes significant morbidity 
and mortality. However, the mechanism underlying progression to CRPC remains 
poorly understood. Here, we report that YAP1, which is negatively regulated by AR, 
influences prostate cancer (PCa) cell self-renewal and CRPC development. Specifically, 
we found that AR directly regulates the methylation of YAP1 gene promoter via the 
formation of a complex with Polycomb group protein EZH2 and DNMT3a. In normal 
conditions, AR recruits EZH2 and DNMT3a to YAP1 promoter, thereby promoting DNA 
methylation and the repression of YAP1 gene transcription. Following ADT treatment 
or when AR activity is antagonized by Bicalutamide or Enzalutamide, YAP1 gene 
expression is switched on. In turn, YAP1 promotes SOX2 and Nanog expression and the 
de-differentiation of PCa cells to stem/progenitor-like cells (PCSC), which potentially 
contribute to disease recurrence. Finally, the knock down of YAP1 expression or the 
inhibition of YAP1 function by Verteporfin in TRAMP prostate cancer mice significantly 
suppresses tumor recurrence following castration. In conclusion, our data reveals that 
AR suppresses YAP1 gene expression through a novel epigenetic mechanism, which 
is critical for PCa cells self-renewal and the development of CRPC.
INTRODUCTION
The development of lethal CRPC is driven by 
complex genetic and epigenetic mechanisms that remain 
poorly understood [1–5]. In a recent study, we identified 
the involvement of YAP1, a key effector of the Hippo 
signaling pathway in the regulation of CRPC growth 
[6]. YAP1 is a transcriptional co-activator that regulates 
the functions of the TEAD and SMAD families of 
transcription factors to promote the expression of genes 
involved in cell cycle, differentiation and metabolism 
[7, 8]. The canonical mammalian Hippo pathway consists 
of MST1/2 and LATS1/2 kinases, which cooperate with 
SAV1 and MOB1 to phosphorylate, thereby inhibit 
YAP1 function [9, 10]. We already provided the first 
evidence that YAP1 activity is under androgen control [6]. 
Androgen treatment represses YAP1 expression in PCa 
cells resulting in reduced cell proliferation and invasion 
capacity. Moreover, nuclear YAP1 accumulates in CRPC 
and the inhibition of YAP1 function with Verteporfin 
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reduces the growth of androgen insensitive tumors in vivo 
[6]. More recently, it was shown that YAP1 could act as a 
coactivator of the AR in conditions of reduced hormonal 
levels [11]. Moreover, in mouse models of PCa, YAP1 
can also regulate the recruitment of polymorphonuclear 
myeloid-derived suppressor cells, which promotes tumor 
growth [12]. Given these initial findings, it is clear that 
YAP1 mode of regulation and mechanism of action in 
urological malignancies merits additional studies.
Here, we explore the mechanisms behind androgen 
regulation of YAP1 function in prostate and provide 
multiple lines of evidence that demonstrate how AR 
directly represses YAP1 gene transcription through DNA 
methylation. In addition, we showed that YAP1 plays a 
critical role in regulating proliferation of prostate cancer 
progenitor-like cells to contribute to the growth of CRPCa.
RESULTS
Androgen-AR signaling suppresses YAP1 gene 
expression
In order to investigate the mechanisms responsible 
for the regulation of YAP1 expression by androgens 
in prostate, firstly, we investigated the regulation of 
YAP1 by AR in vitro. We found increased YAP1 protein 
expression levels following AR knockdown in PCa cells 
(Figure 1A) while treatment of LNCaP cells with AR 
antagonists MDV3100 and Bicalutamide also upregulated 
YAP1 protein levels significantly (Figure 1B) [6]. On the 
other hand, overexpression of ectopic AR in LNCaP cells 
led to reduced YAP1 expression levels (Supplementary 
Figure 1A). Finally, we observed that YAP1 levels in 
clinical samples are negatively correlated with AR levels 
(Figure 1C, Supplementary Figure 1B). Overall, these 
experiments demonstrate that AR regulates nuclear YAP1 
protein levels in human and mouse prostate tissue.
To further investigate the mechanism of YAP1 
repression by AR, we analyzed YAP1 mRNA content 
upon AR knockdown (Figure 1D). The mRNA levels 
of YAP1 and of down-stream target genes CTGF and 
ANKRD increased after AR inactivation, suggesting 
that AR may regulate YAP1 at the level of transcription. 
Indeed, the activity of a luciferase reporter driven by the 
YAP1 gene promoter increased upon AR knockdown or 
after treatment with AR antagonists (Figure 1E). On the 
other hand, androgen stimulation significantly inhibited 
the activity of a YAP1 promoter driven luciferase reporter 
(Supplementary Figure 1C). Inhibition of de novo protein 
synthesis by cyclohexamide treatment showed that the 
turnover of the YAP1 protein did not change significantly 
after androgen receptor inhibition (Figure 1F). Overall, 
these results strongly indicate that YAP1 regulation 
by androgen-AR signaling involves transcriptional 
repression.
AR-mediated repression of YAP1 is associated 
with DNA methylation in the YAP1 promoter 
region
The normal prostate CK5+ basal type of epithelial 
cells express none or low levels of AR [13]. Therefore, 
we predicted that this cell population would be enriched 
for YAP1 nuclear expression and could serve to analyze 
the basis for YAP1 repression by the AR. Indeed, parallel 
analysis of YAP1 and CK5 protein expression in benign 
prostate hyperplasia (BPH), hormone naive PC (HNPC), 
and CRPC tissue revealed that in BPH, endogenous 
YAP1 is predominantly expressed in the nuclei of the 
AR-negative, CK5-positive basal epithelial cells (Figure 
2A, 2B). YAP1 protein was also detected at lower levels in 
AR-expressing luminal cells, where the signal was diffused 
throughout of the cell. In line with our previous findings 
[6], immunofluorescence staining showed that YAP1 
expression was robustly activated in CRPC compared with 
the BPH and HNPC tissues (Figure 2A, 2B). These findings 
were confirmed by Western blot analysis (Supplementary 
Figure 1D). Co-expression of YAP1 and CK5 was also 
found in CRPC tissue, again confirming the elevation of 
YAP1 expression in CK5-positive, AR-low basal-like type 
of PCa cells (Figure 2A, 2B).
It was previously reported that Yap1 gene 
transcription is regulated through epigenetic mechanisms 
in hepatocyte carcinomas [14]. Therefore, we hypothesized 
that the alterations of YAP1 expression in the different 
subtypes of epithelial cells (basal or luminal) are due to the 
variable methylation status of the YAP1 gene, promoter-
associated CpG island regions (shown in Figure 2C). In 
order to test this hypothesis, we used cultured cells from 
primary xenografts obtained from fresh human prostate 
cancer tissue specimens. Through orthotopic inoculation of 
these cells into the prostate of intact or castrated nude mice, 
we established a model of prostate cancer, and confirmed 
via pathological H-E staining and immunohistochemistry 
that the tumors in nude mice were prostate cancer derived 
from human tissue. We cultured cells from tumors grown 
in either intact or castrated mice.  Subsequently, we used 
flow cytometry to separated cell fractions from hormone 
treatment naïve (HNPC) and CRPC cells using CD49f and 
Trop2 antibodies and obtained luminal-like cells (CD49f-, 
Trop2+) and basal-like (CD49f+, Trop2+) cells from both 
HNPC and CRPC tumor cell cultures. The methylation 
profiles of the YAP1 promoter region in luminal and 
basal-like cells were investigated using methylation 
DNA sequencing. The difference of methylation status 
among various groups is significant and in favor of 
higher methylation levels in luminal cells than in basal 
cells (HNPC luminal cells (0.60 ± 0.032) > HNPC basal 
cells (0.47 ± 0.024), CRPC luminal cells (0.31 ± 0.024) > 
CRPC basal cells (0.20 ± 0.028) (P < 0.05, respectively)) 
(Figure 2D, Supplementary Table 1).
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We also performed methylation-specific PCR (MSP) 
to amplify either methylated or unmethylated sulfite-
modified DNA in the promoter-associated CpG islands of 
the YAP1 gene, (Supplementary Table 1). In LNCaP cells, 
MSP product increased after DHT treatment, indicating 
androgen signaling induces methylation at the YAP1 gene 
CpG islands (Figure 2E). Accordingly, when LNCaP 
cells were treated with MDV3100 the amount of MSP 
product decreased (Figure 2E). Treatment with 5-AZA (a 
DNA methylation inhibitor) diminishes the YAP1 CpG 
island methylation (Figure 2F).  Because AR blockage is 
known to induce the expression of DNMT3a [16], we next 
studied how YAP1 expression is modulated by DNMT3a 
knockdown. YAP1 protein levels increased significantly 
upon DNMT3a downregulation (Figure 2G). We observed 
that siRNA mediated targeting of DNMT3a (Figure 2H) 
had little influence on YAP1 mRNA levels in the absence 
of androgens. In contrast, DHT treatment causes a 
significant increase in YAP1 expression in DNMT3a 
knockdown cells causing a clear reversal of androgen-
driven repression of YAP1 gene expression and of YAP1 
promoter driven luciferase activity (Figure 2H, 2I).
The essential role of the AR/DNMT3a/EZH2 
complex in YAP1 transcription
Several studies have shown that the Polycomb 
repressive complex 2 (PRC2) subunit EZH2 and DNMT3a 
can cooperate for transcriptional repression [15]; while 
the interaction between AR and EZH2 has recently been 
shown to be important for regulating genes in prostate 
cancer development [16]. Therefore, we hypothesized 
that AR may recruit the EZH2, DNMT3a complex to 
repress YAP1 expression in PCa cells. To verify this 
hypothesis, we first investigated the interaction between 
AR and DNMT3a or EZH2 in LNCaP cells by co-
Figure 1: Androgen-AR signaling suppresses YAP1 gene expression. (A) The levels of YAP1 protein were measured by Western 
Blot in LNCaP and 22RV1 cells upon AR knockdown. (B) The levels of YAP1 protein were measured in LNCaP cells treated for 24 h with 
the AR antagonist MDV3100 (enzalutamide, 100 nM) and Casodex (Bicalutamide, 10mM). (C) Quantitation of the immunofluorescence 
staining of AR (red) and YAP1(green) in BHP, HNPC and CRPC tissue samples from prostate cancer patients. (D) qPCR measurements 
of AR, PSA, YAP1, ANKRD and CTGF mRNA expression in siAR transfected LNCaP cells. Statistical analysis used Student’s T-Test, 
(*p < 0.05,**p < 0.01). Error bars represent the SD of triplicate measurements. (E) YAP1 promotor driven luciferase activity in LNCaP cell 
transfected with an siRNA targeting the AR or treated with AR antagonist MDV3100. The signal was quantified and statistical significance 
analyzed by Student’s T-Test, (*p < 0.05,**p < 0.01). (F) The levels of YAP1 proteins were measured by Western Blot in LNCaP after 
MDV3100 and CHX treatments for the indicated times.
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Figure 2: AR-mediated repression of YAP1 is associated with DNA methylation of the YAP1 promoter region. (A) 
Immunofluorescence staining (IF) of YAP1 (red) and CK5 (green) in BHP, HNPC and CRPC tissue from human prostate cancer patients. 
Cell nuclei were visualized by DAPI staining. Representative stainings of YAP1 (red) and CK5 (green) in BHP, HNPC and CRPC tissue 
from human prostate cancer patients are shown. (B) Quantitation of YAP1 and CK5 expression from (A). (C) The schematic map of the 
YAP1 promoter-associated CpG island region. (D) Heatmaps showing the levels of YAP1 promoter methylation in four cell lines, HNPC 
cells (luminal and basal) and CRPC cells (luminal and basal). (E, F) DNA methylation PCR (MSP) show levels of YAP1 promotor 
methylation after treatment with DHT (10 nM), MDV3100 (100 nM) or 5AZA (5 μM). (G) Western blot analysis of YAP1 expression in 
LNCaP cell transfected with siRNA targeting DNMT3a (siDNMT3A). (H) qPCR measurement of YAP1 mRNA expression in siDNMT3a 
transfected LNCaP cells with or without DHT treatment. (I) YAP1 gene promoter driven luciferase reporter activity in LNCaP cell after 
treatment with DHT and upon transfection with siDNMT3a.
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immunoprecipitation (Co-IP) experiments. As show in 
Figure 3A, 3B and 3F, the AR forms a stable complex with 
DNMT3a and EZH2. Moreover, AR EZH2 and DNMT3a 
are recruited to the YAP1 gene promoter in response to 
androgen treatment (Figure 3C–3E) Interestingly, the 
ability of AR to form a complex with EZH2 and DNMT3a 
and the recruitment of DNMT3a to the YAP1 promoter 
was abolished by treatment with a EZH2 inhibitor, 
DZNep (Figure 3E–3G). DZNep treatment also lead to 
a significant increase in the expression of YAP1 in the 
presence of androgens (Figure 3H) Likewise, the H3K27 
demethylase inhibitor GSK-J1 increases H3K27me3 levels 
(Supplementary Figure 1E) leading to decreased YAP1 
expression both in the presence or absence of androgens 
(Figure 3H). Thus, our data shows that an active PRC2 
complex is required for androgen-induced, DNMT3A-
mediated repression of YAP1 expression. Together, the 
results indicate that a protein complex containing AR, 
EZH2, and DNMT3a mediates the androgen-driven 
epigenetic repression of the YAP1 gene locus.
YAP1 is required to sustain self-renewal and 
dedifferentiation of prostate cancer cells both in 
Vitro and in Vivo
Adult PCSCs are thought to reside in the basal 
compartment because basal cells can survive androgen 
ablation and give rise to luminal cells [17, 18]. Given our 
previous findings that nuclear YAP1 expression is enriched 
in basal cells, we hypothesized that YAP1 may contribute 
to tumor growth through modulation of PCa progenitor-
like cells. In order to test this hypothesis, we isolated stem/
progenitor-like cells from LNCaP and C4-2 cell cultures 
using antibodies specific for the stem cell markers CD133 
and CD44 [19] and investigated YAP1 expression in these 
cell subpopulations. We observed higher YAP1 expression 
in the CD133high and CD44high stem/progenitor-like cells as 
compared to unselected control cells and to CD133low or 
CD44low cells (Figure 4A).
To determine if YAP1 regulates the maintenance 
of PCa stem/progenitor cells, we tested whether YAP1 
knockdown altered the ability of PCSCs to self-renew. 
We silenced the YAP1 gene using a YAP1 shRNA 
targeting vector and upon culturing multiple clones of 
YAP1 reduced C4-2 cells, we observed a decreased 
percentage of sphere forming cells. These prostate spheres 
were characterized by smaller, less dense morphologies 
compared with control cells (Supplementary Figure 1F). 
We also knocked down YAP1 from CD133high LNCaP cells 
to check their ability to form spheres when cultured. We 
found that YAP1-reduced CD133high LNCaP cells formed 
significantly fewer spheres than control cells (Figure 4B). 
On the other hand, we overexpressed YAP1 in CD133low 
LNCaP cells and found an increased number of prostate 
spheres (Figure 4C). We also examined the expression 
of bona fide stem cell markers, including Oct4, Nanog, 
Figure 3: The essential role of the AR–DNMT3a and EZH2 complex in the regulation of YAP1 expression. (A) 
Immunoprecipitation of AR in LNCaP cells followed by immunoblot analysis of EZH2, DNMT3a. IgG represents a control antibody 
used for IPs. (B) Co-IP of EZH2 and AR, DNMT3a in LNCaP cells (C) ChIP–PCR analysis of AR on YAP1 promoter. LNCaP cells were 
hormone starved for 12 h and then treated with ethanol, R1881 (10 nM) or DZNep (10 μM) for 6 h. Cells were then harvested for ChIP 
and analyzed by qPCR using. (D) ChIP–PCR analysis of EZH2 binding to the YAP1 gene promoter. (E) ChIP–PCR analysis of DNMT3a 
binding to the YAP1 gene promoter. LNCaP cells were treated with ethanol, R1881 or DZNep as indicated (F) Immunoprecipitation of AR 
in LNCaP cells treated with DZNep followed by immunoblot analysis of AR, EZH2 and DNMT3a. (G) IP with DNMT3a Ab in LNCaP 
cell treated with DZNep (10 μM) followed by immunoblot analysis of EZH2 AR and DNMT3a. (H) LNCaP cells were hormone starved for 
12 h and then treated with ethanol or R1881 (10 nM), DZNep (10 μM) and GSKJ1(10 μM) for 8 h, WB analysis of YAP1 and AR protein 
expression.
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C-met and Sox2 using real-time PCR. Consistent with 
the previously described morphological changes, the 
mRNA expression levels of Oct4, Nanog, C-met and Sox2 
strongly decreased in YAP1 knockdown cells compared to 
control PCSC (Figure 4D). Altogether, these data suggest 
that YAP1 is required to sustain self-renewal.
As CD133low LNCaP cells express low levels of 
YAP1, we stably transfected these cells with a YAP1 cDNA 
expression vector and generated YAP1 overexpressing 
CD133low LNCaP cells, named CD133low YAP1wt. Then, 
we explored the in vivo tumorigenicity of parental LNCaP, 
CD133low and CD133low YAP1wt LNCAP cells. Although 
parental and CD133low LNCP cells exhibited reduced 
capacity to generate tumors, YAP1 transfected CD133low 
LNCAP cells clearly showed increased tumor forming 
capacity (Figure 4E). Next, we analyzed the expression 
of YAP1, of stem cell markers CD133, Nanog and SOX2 
and of proliferation marker Ki67 in the xenograft tumors 
originated from these three cell lines using IHC staining 
(Figure 4F and Supplementary Figure 2). We found the 
expression of YAP1 to correlate with that of Nanog, SOX2 
and Ki67, being higher in tumors of CD133low YAP1wt 
than in tumors of LNCaP control cells and CD133low cells 
(Figure 4F).
YAP1-mediated stem cell renewal is dependent 
upon the TEAD-interaction domain of YAP1
To further analyze the function of YAP1, we reduced 
the expression levels of YAP1 in C4-2 cells using YAP1 
targeting siRNAs. In these cells, we found decreased 
SOX2 and Nanog protein expression (Figure 5A). We also 
investigated how YAP1 regulates the expression of these 
genes. Generally, YAP1 is composed of a TEAD-binding 
domain, a SH3-binding motif and two WW domains [20] 
(Supplementary Figure 3A). To identify which domain 
is responsible for promoting stem cell renewal, we 
expressed YAP1 domain-specific mutants in C4-2 cells 
to assess their effect on YAP1 function using previously 
characterized YAP1 TEAD-binding domain (YAP1-
S94A), WW domain and SH3 domain (YAP1-S369A) 
mutants [21–23]. We observed a lower level of SOX2 and 
Nanog mRNA expression in YAP1-S94A expressing cells 
compared with cells transfected with YAP1-WT and other 
YAP1 mutants (Figure 5B). We also observed that YAP1-
WT cells expressed increased levels of SOX2 and Nanog 
proteins compared to control cells, but cells expressing the 
YAP1-S94A mutant showed barely detectable levels of 
SOX2 and Nanog (Supplementary Figure 3B). To analyze 
whether YAP1 directly trans-activates SOX2 and Nanog 
gene promoters, we utilized a reporter assays to show 
that both SOX2 and Nanog gene promoters were strongly 
activated by transfection of wt-YAP1 and WW-YAP1 and 
S369A-YAP1 mutants, but to a much smaller extent by 
the YAP1-S94A variant (Figure 5C, 5D). These results 
show that the TEAD-binding domain of YAP1 plays a 
crucial role for the activation of SOX2 and Nanog gene 
transcription.
On a functional level, the number of spheroids 
formed by C4-2 cells over expressing wt-YAP1, and the 
YAP1-S369A mutants or YAP1-WW domain mutants 
significantly increased compared to control cells, 
suggesting that the WW domains and SH3 domain are 
not essential for YAP-mediated stem cell renewal in these 
conditions. On the other hand, cells expressing the YAP1-
S94A mutant form significantly fewer spheres than control 
cells (Figure 5E). Together, these results suggest that 
integrity of the YAP1 TEAD-binding domain is require 
for YAP1 functions in prostate cancer cells renewal.
Interestingly, the capacity of LNCap cells to form 
spheres increased slightly upon transfection of an shRNA 
against AR, while shRNA against YAP1 decreased the 
number of spheres alone or in the background of AR 
knock-down (Figure 5F). Furthermore, knockdown SOX2 
in C4-2 cells decreased the number of sphere forming 
cells even upon transfection with the YAP1-wt expression 
vector (Figure 5G). This suggests that the growth of PCSC 
after ADT is modulated largely through the actions of 
YAP1 on SOX2.
Blocking YAP1 signaling increases the 
effectiveness of ADT
To further define whether increased YAP1 
expression regulate CRPC development, lentivirus-
shRNA mediated knockdown of YAP1 or treatment with 
YAP1 antagonist, Verteporfin [24] was used on LNCaP 
xenografts and TRAMP mice models. First, we used 
lentivirus shRNA-YAP1 to knockdown YAP1 expression 
in the prostate of TRAMP mice (20weeks) and analyzed 
the tumors after two weeks of treatment. We observed that 
tumors of the sh-YAP1 lentivirus group were smaller than 
control group (Figure 6A). IHC analysis confirmed that 
these tumors express less YAP1 and also show greatly 
reduced SOX2 and Ki67 protein levels, suggesting that 
both tumor cell proliferation and the number of progenitor/
stem like cells are regulated by YAP1 expression in vivo 
(Figure 6B, Supplementary Figure 4).
Next, we tested the effects of Verteporfin, an FDA 
approved drug with known effects on the regulation 
of YAP1 content and activity [6]. LNCaP xenograft-
bearing mice started to receive treatment until tumors 
reached a size of approximately 120 mm3, and TRAMP 
mice received YAP1- blocking treatment at week 22. 
The mice were castrated at week 12, the time they start 
to bear tumors [25]. When mice bearing LNCaP hormone 
sensitive tumors were treated with Verteporfin alone, 
the growth of these tumors showed a slight reduction 
in size (Figure 6C–6E, Supplementary Figure 5). 
Likewise, Verteporfin treatment of LNCaP-castration 
resistant tumors significantly suppressed tumor growth in 
comparison to both non-castrated control group and the 
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castrated group (Figure 6C–6E, Supplementary Figure 5). 
We observed that Verteporfin treated tumors expressed 
reduced levels of YAP1, which are accompanied by 
diminished cell proliferation, and decreased expression of 
Ki67, SOX2 and Nanog markers. In the TRAMP model, 
we did not detect significant differences in tumor growth 
after castration or after Verteporfin treatments alone. In 
contrast, combined castration and Verteporfin treatments 
caused a significant reduction in tumor weight (Figure 
6F, 6G, Supplementary Figure 6). Together, these results 
highlight the potential of targeting the YAP1 signaling to 
sensitize to anti-androgen therapy.
DISCUSSION
In this study, we unveil key elements of the crosstalk 
between the AR and the Hippo signaling pathways and 
its implications for prostate carcinogenesis. Our study 
Figure 4: YAP1 is required to sustain self-renewal and dedifferentiation of prostate cancer cells in vitro and in vivo. 
(A) LNCaP cells and C4-2 cell subpopulations were isolated using magnetic sorting with antibodies recognizing stem cell markers, CD133 
and CD44. Protein levels of YAP1, CD133 and CD44 were analyzed by Western Blot in control and CD133 or CD44 high or low cells. 
(B) Quantitation of sphere formation capacity of C4-2, CD133high cells transfected with sh-control or sh-YAP1 expression vectors. (C) 
Quantitation of sphere formation capacity of C4-2, CD133low cells transfected with either control or YAP1-wt expression vectors. (D) 
mRNA expression of stem cell marker genes: CD44, CD133, SOX2, OCT4, Nanog, C-met and YAP1 by qPCR after siRNA mediated 
knockdown of YAP1 expression in C4-2 cells. (E) CD133low cell, CD133low-YAP1wt expressing cell and LNCaP cell were transplanted 
into nude mice subcutaneously and tumor growth was monitored daily. Growth curves are shown. P values were determined by paired t 
test. *p < 0.05, **p < 0.01, ***p < 0.001 (F) Quantitation of YAP1, Ki67 and CD133 protein expression in mice tumors using IHC. See also 
Supplementary Figure 2.
Oncotarget115061www.impactjournals.com/oncotarget
demonstrates that the AR assembles at the YAP1 promoter 
a repressive complex containing DNMT3A and EZH2 to 
suppress YAP1 transcription. Consequently, androgen 
deprivation therapy can induce YAP1 expression, which 
in turn regulates downstream factors such as SOX2 and 
Nanog to promote PCa stem/progenitor like cells and 
contribute to castration resistant prostate cancer growth 
(Figure 6H).
When activated by ligands, the AR binds to genomic 
androgen-response elements (AREs), which serve as a 
platform for recruitment of basal transcriptional factors 
and co-regulators to modulate gene transcription [26]. A 
few reports have studied AR inhibition of transcription. 
Some studies have hinted a indirect mechanisms of AR 
regulated transcriptional repression [27, 28], while others 
have shown the existence of direct mechanisms involving 
the EZH2 containing PRC2 repressive complex [29]. 
Using YAP1 as a model, we found that AR also inhibits 
gene expression by hormone induced recruitment of 
DNMT3a to the AR/EZH2 complex leading to methylation 
of promoter CpG islands resulting in epigenetic silencing. 
Consequently, ADT restores YAP1 expression due to 
the loss of AR-EZH2-DNMT3a association to the YAP1 
promoter.
Our current understanding of the pathways the 
regulation of YAP1 proteins levels emphasizes the 
phosphorylation driven mechanisms that promote 
ubquitination dependent YAP1 degradation [9]. In 
contrast, androgen regulation of YAP1 levels seems to 
be mainly transcriptionally controlled because the rate of 
YAP1 protein degradation is not affected by AR blockage. 
The transcriptional control of YAP1 expression was also 
highlighted in a recent study by Nguyen LT. et al that 
show that probasin-driven ERG expression in mice leads 
Figure 5: YAP1-mediated stem cell renewal depends on the TEAD-Interaction Domain of YAP1. (A) Western blot analysis 
of SOX2 and Nanog protein expression in C4-2 cells transfected with siYAP1 and siControl. (B) qPCR measurements of mRNA expression 
levels of SOX2, Nanog and PSA in C4-2 cells transfected with control, YAP1wt or YAP1-S94A, YAP1-WW and YAP1-S369A mutant 
expression vectors as indicated. (C, D) SOX2 and Nanog gene promoter driven luciferase reporter activity in C4-2 cell transfected with 
expression vector for YPA1-WT or YAP1 mutants as indicated. (E) Sphere formation activity of C4-2 cells transfected with expression 
vectors for YAP1-WT and YAP1 variants as indicated. (F) Sphere formation activity  and Western blot analysis of AR, YAP1 and SOX2 
expression in C4-2 cells transfected with shAR and shYAP vectors. (G) Sphere formation activity of C4-2 cells transfected with YAP1wt 
vector and siRNA targeting SOX2.
Oncotarget115062www.impactjournals.com/oncotarget
Figure 6: Blocking YAP1 signaling increases the effectiveness of ADT. (A) 20 weeks old TRAMP mice were treated with 
lentivirus targeting YAP1 or with corresponding controls . The prostate tumors were harvested at 24 weeks of age. 3 mice were used in 
each group. (B) Quantitation of Ki-67, YAP1 and SOX2 expressions in TRAMP mice tumors from each group, specimens were obtained 
at 14 days post treatment. The IHC was scored according to number of cells expressing the indicated proteins and statistical analysis was 
performed using the non-parametric Kruskal-Wallis test in order to determine significance. See also Supplementary Figure 5. (C) Castration 
resistant and castration naïve LNCaP cells derived xenografts were injected subcutaneously in BalbC/ nude mice [8]. Tumors were allowed 
to grow until they reached a size of approximately 120 mm3. Subsequently, xenografted mice were randomized to receive either vehicle or 
100 mg/kg Verteporfin (VP) daily for 9 days by intraperitoneal injections. The proliferation of tumors was monitored. 6 mice were used in 
each group. Statistical significance differences in tumor size were analyzed by Student’s T-Test, (*p < 0.05, **p < 0.01). (D) Tumor weight 
in each group is shown. (E) Quantitation of Ki-67, YAP1, Nanog and SOX2 expressions in LNCaP xenograft tumors from each group. 
Specimens were obtained 10 days post-treatment. The IHC was scored according to the number of cells expressing the indicated proteins 
and statistical analysis was performed (non-parametric Kruskal-Wallis test) in order to determine significance. See also Supplementary 
Figure 5. (F) 12wks old TRAMP mice were randomized, castrated and then divided into naive and castration groups. At 18 weeks of age 
mice received 100 mg/kg Verteporfin (VP) daily, for 14 days by intraperitoneal injection. The prostate tumors were harvested at 24wks 
(n = 6 mice per group). (G) Quantitation of Ki-67, YAP1, Nanog and SOX2 expressions in TRAMP tumors from each group at 24wks. 
The IHC was scored according to number of cells expressing the indicated proteins and statistical analysis was performed (non-parametric 
Kruskal-Wallis test) in order to determine significance. *p < 0.05, **p < 0.01. See also Supplementary Figure 6, (H) Hypothetical model of 
AR- DNMT3a complex role in inhibition of YAP1 signaling. In prostate cancer cells, AR binds EZH2 and DNMT3a proteins to form a 
complex associated with the YAP1 promoter where DNMT3a induces DNA methylation to inhibit YAP1 gene transcription.
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to tumor formation in aged mice that are characterized 
by YAP1 overexpression [30]. In this model, the levels 
of active MST and LATS kinases do not change in 
comparison to control mice and paradoxically the levels 
of YAP1 phosphorylated in S127, which should lead to 
inhibition of YAP1 function also increase, suggesting 
that LATS1/2, MST1/2 actions on YAP1 may not be 
the primary factor controlling its activity in vivo [31]. 
Instead, the authors demonstrate that ERG can induce the 
transcriptional activation of the YAP1 gene by promoting 
H3 acetylation. Given that ERG is able to antagonize AR 
function in prostate cancer cells [30], it will be interesting 
to explore whether ERG regulation of YAP1 also relies on 
antagonizing the repressing actions of the AR/DNMT3a 
complex.
Prostate epithelium is composed of three types 
of cells: luminal, basal and neuroendocrine cells [32]. 
Several independent studies have verified that basal 
cells in human and murine prostates can generate all 
three prostate epithelial cell lineages [33], although 
prostate stem cell-like populations have been identified 
in both the basal and luminal layers [19, 34]. The Hippo 
signaling pathway plays a functional role on cancer 
cell differentiation in various organs [35]. In this study, 
we proved that YAP1 protein expression is elevated in 
CD133high progenitor type of prostate cell  and found that 
YAP1 overexpression inhibits PCSC differentiation and 
maintains PCSC features. Conversely, YAP1 knockdown 
results in loss of PCSC properties. Furthermore, YAP1 
overexpression promotes CD133low cells to de-differentiate 
into CD133high stem cells-like cells that efficiently generate 
tumors when injected in mice. We also proved that YAP1 
activation positively regulates the expression of Nanog 
and Sox2, while inhibition of YAP1 with Verteporfin or its 
knockdown by means of shRNA reduce cell proliferation 
alongside with diminished Sox2 expression. Therefore, it 
is possible that activated YAP1 in basal or intermediate 
cells enhances stem/progenitor cell expansion through 
transcriptional induction of Nanog and Sox2 [36].
Several non-overlapping mechanisms have been 
proposed to explain YAP1 effects on tumorgenesis, 
including promotion of epithelial-mesenchimal transition 
(EMT), resistance to anoikis, and induction of stem cell 
properties [10]. Here, we show that YAP1 contributes 
to the growth of castration resistance tumors via a de-
differentiation mechanism leading to increased cell 
proliferation. Our findings does not exclude that additional 
YAP1 driven mechanisms such as the activation of AR 
[11] or immunomodulation [12] may also play a role in 
stimulating the growth of castration resistant tumors. 
Clearly, the exploration of YAP1 function is prostate 
cancer is in its infancy and additional studies are 
warranted. Given the results obtained in our pre-clinical 
models, it may be clinically relevant to explore novel 
therapeutic strategies to target AR and YAP1 pathways 
simultaneously in PCa treatment.
MATERIALS AND METHODS
Cell culture
The PCa cell line LNCaP-FGC was obtained from 
the American Tissue Culture Collection (Manassas, VA) 
and the C4-2 cells were obtained from the MD Anderson 
Cancer Center, University of Texas. Cells were maintained 
in RPMI 1640 medium supplemented with 10% FBS, 1% 
penicillin/streptomycin, and 1% glutamine. DHT was 
obtained from Amersham (Braunschweig, Germany), 
DZNep was from SELLECK (S71201) and MDV3100 
was from Haoyuan Chemexpress (Shanghai, China).
Plasmids
The hYAP1-Wt expression vector consists of 
the full-length YAP1 open reading frame cloned into 
pcDNA3.1 and was donated by Dr. Ka-Fai from Hong 
Kong SAR, PR China. YAP1 mutants were obtained from 
Addgene: YAP1-S94A ( #33102), YAP1wt (#19045), WW 
mutant (#19048) and S369A (#18995). The Nanog-LUC 
reporter gene was donated by Dr. Yanhong Shi from CA, 
USA. The YAP1 promoter-LUC construct was bought 
from GeneCopoeia.
Sphere formation assay
Single cell suspensions (1 × 103, in 60 μl of medium) 
were mixed with 60 μl of cold Matrigel, and the mixture 
was placed along the rim of the 24-well plates. The culture 
plates were placed in a 37°C incubator for 10 min to let 
the mixture solidify, and 500 μl of medium was then 
added into the well. Sphere numbers were counted after 
7–14 days under an Olympus light microscope, and size 
differences were also examined. A minimum of triplicate 
experiments were performed.
Co-immunoprecipitation and western blotting
LNCaP cells were hormone starved for 12h and then 
treated with ethanol, R1881 (10nM) or DZNep (10mM) for 
6 h. Cells were lysed in a buffer containing 150 mM KCl,75 
mM Hepes, pH 7.5, 1.5 mM EGTA, 1.5 mM MgCl2, 10% 
glycerol, and 0.075% NP-40 supplemented with a cocktail 
of protease inhibitors [Roche,USA]. Extracts were pre-
cleared using a mixture of protein A–Sepharose (CL-
4B; GE Healthcare) or protein G-Sepharose (rec-Protein 
G-Sepharose 4B; Invitrogen) and immunoprecipitations 
were performed for 1 hour at 4˚C. Immunoprecipitates 
were washed with lysis buffer, resuspended in sample 
buffer, boiled and analyzed by SDS-PAGE. Individual 
samples (40 μg of protein) were separated on 8–10% SDS 
polyacrylamide gel and transferred to PVDF membranes 
(Millipore, Billerica, MA). Membranes were blocked in 
a PBS-Tween 20 solution with 5% fat-free milk for 1h at 
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room temperature, and subsequently the membranes were 
incubated with appropriate dilutions of specific primary 
antibodies, overnight at 4°C. After washing, the blots 
were incubated with HRP conjugated anti-rabbit or anti-
mouse IgG for 1h. The blots were developed by enhanced 
chemiluminiscence (Vector Laboratories, Burlingame, CA) 
and visualized by Imager.
RNA extraction and gene array analysis
RNA was extracted using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instructions. 
RNAs (1 ug) were subjected to reverse transcription using 
Superscript III transcriptase (Invitrogen). The obtained 
cDNAs were used for qPCR using a Bio-Rad CFX96 
system with SYBR Green. The primers used are listed 
in Table 1. Expression levels were normalized to the 
expression of the GAPDH gene. .
Luciferase assays
For the dual luciferase assay, LNCaP and C4-2 cells 
were plated into 12-well plates and co-transfected with 
1 μg of the seap reporter gene construct and 15 pmol of 
YAP1 luciferase together with siRNA of other plasmids by 
using transfection reagent (Roche). Transfected cells were 
Table 1: The expression levels of methylation in four cell lines, HNPC cell (luminal and basal), 
CRPC cell (luminal and basal)
name:YAP1 HNPC • basel HNPC • luminal CRPC • basel CRPC • luminal
SampleID CPG • Position Y1 Y2 Y3 Y4
YAP1_CpG_1 102 0.47 0.55 0.22 0.3
YAP1_CpG_2 110 0.46 0.65 0.16 0.23
YAP1_CpG_3.4 139:141 0.45 0.57 0.25 0.27
YAP1_CpG_5 153 0.42 0.62 0.26 0.33
YAP1_CpG_6.7.8 161:166:170 0.47 0.41 0.27 0.21
YAP1_CpG_9 179 0.42 0.49 0.32 0.34
YAP1_CpG_10.11 187:189 0.47 0.56 0.19 0.28
YAP1_CpG_12 209 0.48 0.65 0.18 0.3
YAP1_CpG_15 260 0.51 0.55 0.21 0.29
YAP1_CpG_16.17 271:280 0.49 0.52 0.19 0.33
YAP1_CpG_18.19 286:290 0.47 0.62 0.17 0.27
YAP1_CpG_20 304 0.48 0.58 0.18 0.26
YAP1_CpG_21 308 0.46 0.56 0.16 0.32
YAP1_CpG_22 313 0.51 0.62 0.19 0.35
YAP1_CpG_23.24.25.26 338:342:344:351 0.45 0.61 0.25 0.29
YAP1_CpG_27 367 0.53 0.64 0.23 0.32
YAP1_CpG_28 373 0.49 0.63 0.24 0.28
YAP1_CpG_29.30.31.32 387:393:398:340 0.5 0.48 0.2 0.29
YAP1_CpG_33 412 0.58 0.55 0.22 0.27
YAP1_CpG_37.38.39 444:446:450 0.59 0.55 0.23 0.36
YAP1_CpG_40 457 0.59 0.55 0.24 0.32
YAP1_CpG_41 462 0.45 0.63 0.25 0.31
YAP1_CpG_42 472 0.48 0.6 0.26 0.33
YAP1_CpG_43 476 0.46 0.65 0.27 0.34
YAP1_CpG_44.45.46 483:487:491 0.48 0.64 0.18 0.35
YAP1_CpG_47.48.49.50 500:503:505:510 0.52 0.49 0.22 0.28
We design primer from -697 to -160 of YAP1 promtor enriched CG, and use a MassARRAY Compact MALDI-
TOF(Sequenom), and spectra’s methylation ratioswe regenerated by the Epi-TYPER  software  v1.0 (Sequenom) in in four 
cell lines, HNPC cell (luminal and basal), CRPC cell (luminal and basal). Heatmaps showing higher methylation levels in 
luminal cells than those in basal cells.
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cultured and 24 h later the supernatants were collected 
for luciferase assay using Dual Luminescence assay kit 
(GeneCopoeia MD) according to the manufacturer’s 
instructions. To measure SOX2 and Nanog promoter 
driven luciferase activity, the Glo Luciferase Assay 
System (Promega ) was used.
Chromatin immunoprecipitation
LNCaP cells were grown in RPMI 1640 media 
(Invitrogen) supplemented with 10% charcoal-stripped 
FBS (CSF, HyClone, USA) for 12 h before stimulation 
with 1 × 10-9 M synthetic androgen R1881 or an equal 
volume of ethanol for 6 h. DNA cross-linking was 
performed by adding 1% formaldehyde into the cell 
cultures at room temperature for 10 min when glycine was 
added (0.125 M final concentration) for 5 min to stop the 
cross-linking reaction. Cells were lysed with a lysis buffer 
containing protease inhibitors and sonicated to shear 
genomic DNA to lengths between 200 and 1000 bp. One-
tenth of the cell lysate was used for input control, and the 
rest was used for immunoprecipitation using AR, DNMT3a 
or EZH2 antibody. After collecting the immunoprecipitates 
using protein G-agarose columns, protein-DNA complexes 
were eluted and heated at 65°C to reverse the cross-
linking. Following digestion with proteinase K, DNA 
fragments were purified using spin columns and analyzed 
using PCR for 35 cycles in a sequence of 94°C for 30s, 
57°C for 30 s, and 72°C for 1 min. Specific primer sets 
were designed to amplify a target sequence within the 
human YAP1 promoter (Supplementary Table 2). PCR 
products were electrophoresed in a 1% agarose gel with 
ethidium bromide and visualized under ultraviolet light.
Confocal fluorescence analysis
Cells were grown on Labtek II-CC2 Chamber slides 
(Nunc), fixed with 4% paraformaldehyde for 5 minutes, 
washed with PBS and blocking buffer (PBS with 5% BSA 
and 0.1% Triton X- 100), and then incubated overnight at 
4°C in primary antibodies against YAP1, AR and CK5. 
Secondary antibodies were Donkey anti-mouse, -rabbit 
or -goat coupled to Alexa-350, -488 or -647 (Invitrogen). 
Cell nuclei were visualized with DAPI (Sigma).
Animal studies
Four-week-old male Balb/c mice (HFK Bio-
Technology Co. Ltd, Beijing) were injected subcutaneously 
with 2 × 106 LNCaP cells suspended in 0.1 mL of Matrigel 
(BD Biosciences), and were implanted subcutaneously into 
the dorsal flank on both sides of the mice. Once the tumors 
reached an indicated size, the animals were randomized and 
received castration and/or daily treatment with 100 mg/kg 
body weight of Verteporfin by intraperitoneal injection for 
9 days. Tumor volume was recorded by digital caliper and 
estimated using the formula LW2/2, where L = length of 
tumor and W = width. At the end of the study, mice were 
killed and tumors extracted and weighed. For TRAMP 
mice, we verified the genotypes by PCR using tail snip 
DNA as templates [30].Verified mice were randomized 
and received castration at 12wk-old age. For treatment, te 
lentiviral vector-expressing short hairpin (shRNA) YAP1 
(1 × 108) was injected into the tumor Verteporfin, 100 mg/
kg body weight was given daily by intraperitoneal injection 
for 14 days. At the end of the studies, mice were killed and 
tumors extracted and weighed. All procedures involving 
mice were approved by the University Committee on Use 
and Care of Animals at the Tianjin Medical University and 
conform to all international regulatory standards.
Statistical analysis
Data is expressed as mean ± SD. Differences 
between samples were analyzed by Student's T-test. 
P-values of 0.05 or less were considered significant.
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